BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Evans C, Zhu F, Kingwell E, Shirani A, van der Kop ML, Petkau J, Gustafson P, Zhao Y, Oger J, Tremlett H. Association between beta-interferon exposure and hospital events in multiple sclerosis: BETA-INTERFERON AND HOSPITALIZATIONS IN MS. Pharmacoepidemiol Drug Saf 2014;23:1213-22. [DOI: 10.1002/pds.3667] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Wijnands JMA, Zhu F, Kingwell E, Fisk JD, Evans C, Marrie RA, Zhao Y, Tremlett H. Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study. J Neurol Neurosurg Psychiatry 2018;89:1050-6. [PMID: 29602795 DOI: 10.1136/jnnp-2017-317493] [Cited by in Crossref: 49] [Cited by in F6Publishing: 43] [Article Influence: 12.3] [Reference Citation Analysis]
2 Kingwell E, Leray E, Zhu F, Petkau J, Edan G, Oger J, Tremlett H. Multiple sclerosis: effect of beta interferon treatment on survival. Brain 2019;142:1324-33. [PMID: 30883636 DOI: 10.1093/brain/awz055] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 9.5] [Reference Citation Analysis]
3 Evans C, Marrie RA, Zhu F, Leung S, Lu X, Kingwell E, Zhao Y, Tremlett H. Adherence to disease-modifying therapies for multiple sclerosis and subsequent hospitalizations. Pharmacoepidemiol Drug Saf 2017;26:702-11. [PMID: 28370875 DOI: 10.1002/pds.4207] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
4 de Jong HJI, Kingwell E, Shirani A, Cohen Tervaert JW, Hupperts R, Zhao Y, Zhu F, Evans C, van der Kop ML, Traboulsee A, Gustafson P, Petkau J, Marrie RA, Tremlett H; British Columbia Multiple Sclerosis Clinic Neurologists. Evaluating the safety of β-interferons in MS: A series of nested case-control studies. Neurology 2017;88:2310-20. [PMID: 28500224 DOI: 10.1212/WNL.0000000000004037] [Cited by in Crossref: 29] [Cited by in F6Publishing: 9] [Article Influence: 5.8] [Reference Citation Analysis]
5 Al-sakran LH, Marrie RA, Blackburn DF, Knox KB, Evans CD. Predictors of hospitalization in a Canadian MS population: A matched cohort study. Multiple Sclerosis and Related Disorders 2020;41:102028. [DOI: 10.1016/j.msard.2020.102028] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
6 McKay KA, Evans C, Fisk JD, Patten SB, Fiest K, Marrie RA, Tremlett H. Disease-Modifying Therapies and Adherence in Multiple Sclerosis: Comparing Patient Self-Report with Pharmacy Records. Neuroepidemiology 2017;48:124-30. [PMID: 28683461 DOI: 10.1159/000477771] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
7 Ng HS, Zhu F, Kingwell E, Zhao Y, Yao S, Ekuma O, Svenson LW, Evans C, Fisk JD, Marrie RA, Tremlett H. Disease-modifying drugs for multiple sclerosis and subsequent health service use. Mult Scler 2021;:13524585211063403. [PMID: 34949130 DOI: 10.1177/13524585211063403] [Reference Citation Analysis]